{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:56:52Z","timestamp":1791291412395,"version":"4.3.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Personalized therapy for bone metastases should consider the patients\u2019 remaining lifespan. Estimation of survival can be facilitated with scoring tools. A new tool was developed, specifically designed to estimate 12-month survival.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In 445 patients irradiated for bone metastases, radiotherapy regimen plus 13 factors (age, gender, Karnofsky performance score (KPS), primary tumor type, interval between cancer diagnosis and RT of bone metastases, visceral metastases, other (non-irradiated) bone metastases, sites of bone metastases, number of irradiated sites, pathological fracture, fractionation of RT, pre-RT surgery, pre-RT administration of bisphosphonates\/denosumab, pre-RT systemic anticancer treatment) were retrospectively analyzed for survival. Factors achieving significance (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) or borderline significance (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.055) on multivariate analysis were used for the scoring system. Twelve-month survival rates were divided by 10 (factor scores); factor scores were summed for each patient (patient scores).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>On multivariate analysis, survival was significantly associated with KPS (hazard ratio (HR) 1.91, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and primary tumor type (HR 1.12, p\u2009&lt;\u20090.001); age achieved borderline significance (HR 1.14, <jats:italic>p<\/jats:italic>\u2009=\u20090.054). These factors were used for the scoring tool. Patient scores ranged from 8 to 17 points. Three groups were designated: 8\u20139 (A), 10\u201314 (B) and 15\u201317 (C) points. Twelve-month survival rates were 9, 38 and 72% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001); median survival times were 3, 8 and 24\u2009months.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This new tool developed for patients irradiated for bone metastases at any site without spinal cord compression allows one to predict the survival of these patients and can aid physicians when assigning the treatment to individual patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-019-6385-7","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T14:03:55Z","timestamp":1574949835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prognostic factors and a new scoring system for survival of patients irradiated for bone metastases"],"prefix":"10.1186","volume":"19","author":[{"given":"Dirk","family":"Rades","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha","family":"Haus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Schild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"key":"6385_CR1","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s\u20139s.","journal-title":"Clin Cancer Res"},{"key":"6385_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrclinonc.2010.17","volume":"7","author":"D Rades","year":"2010","unstructured":"Rades D, Schild SE, Abrahm JL. Treatment of painful bone metastases. Nat Rev Clin Oncol. 2010;7:220\u20139.","journal-title":"Nat Rev Clin Oncol"},{"key":"6385_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S0360-3016(02)04147-0","volume":"55","author":"JS Wu","year":"2003","unstructured":"Wu JS, Wong R, Johnston M, Bezjak A, Whelan T. Cancer Care Ontario practice guidelines initiative supportive care group: meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003;55:594\u2013605.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6385_CR4","volume":"2","author":"WM Sze","year":"2004","unstructured":"Sze WM, Shelley M, Held I, Mason M. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. Cochrane Database Syst Rev. 2004;2:CD004721.","journal-title":"Cochrane Database Syst Rev"},{"key":"6385_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clon.2011.11.004","volume":"24","author":"E Chow","year":"2012","unstructured":"Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24:112\u201324.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"6385_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s000660050061","volume":"175","author":"S Koswig","year":"1999","unstructured":"Koswig S, Budach V. Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther Onkol. 1999;175:500\u20138.","journal-title":"Strahlenther Onkol"},{"key":"6385_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ijrobp.2014.07.051","volume":"90","author":"PG Westhoff","year":"2014","unstructured":"Westhoff PG, de Graeff A, Monninkhof EM, Bollen L, Dijkstra SP, van der Steen-Banasik EM, van Vulpen M, Leer JW, Marijnen CA, van der Linden YM. Dutch bone metastasis study group: an easy tool to predict survival in patients receiving radiation therapy for painful bone metastases. Int J Radiat Oncol Biol Phys. 2014;90:739\u201347.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6385_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","volume":"12","author":"S Qin","year":"2019","unstructured":"Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019;12:27.","journal-title":"J Hematol Oncol"},{"key":"6385_CR9","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974\u201382.","journal-title":"J Clin Oncol"},{"key":"6385_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/neuonc\/not318","volume":"16","author":"L Bollen","year":"2014","unstructured":"Bollen L, van der Linden YM, Pondaag W, Fiocco M, Pattynama BP, Marijnen CA, Nelissen RG, Peul WC, Dijkstra PD. Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1,043 patients. Neuro-Oncology. 2014;16:991\u20138.","journal-title":"Neuro-Oncology"},{"key":"6385_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2106\/JBJS.16.01514","volume":"100","author":"JJ Willeumier","year":"2018","unstructured":"Willeumier JJ, van der Linden YM, van der Wal CWPG, Jutte PC, van der Velden JM, Smolle MA, van der Zwaal P, Koper P, Bakri L, de Pree I, Leithner A, Fiocco M, Dijkstra PDS. An easy-to-use prognostic model for survival estimation for patients with symptomatic long bone metastases. J Bone Joint Surg Am. 2018;100:196\u2013204.","journal-title":"J Bone Joint Surg Am"},{"key":"6385_CR12","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/cncr.25223","volume":"116","author":"D Rades","year":"2010","unstructured":"Rades D, Douglas S, Veninga T, Stalpers LJ, Hoskin PJ, Bajrovic A, Adamietz IA, Basic H, Dunst J, Schild SE. Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. Cancer. 2010;116:3670\u20133.","journal-title":"Cancer"},{"key":"6385_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/1471-2407-12-302","volume":"12","author":"D Rades","year":"2012","unstructured":"Rades D, Douglas S, Veninga T, Schild SE. A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer. 2012;12:302.","journal-title":"BMC Cancer"},{"key":"6385_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00066-012-0230-0","volume":"189","author":"D Rades","year":"2013","unstructured":"Rades D, Douglas S, Schild SE. A validated survival score for breast cancer patients with metastatic spinal cord compression. Strahlenther Onkol. 2013;189:41\u20136.","journal-title":"Strahlenther Onkol"},{"key":"6385_CR15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/nrclinonc.2010.137","volume":"7","author":"D Rades","year":"2010","unstructured":"Rades D, Abrahm JL. The role of radiotherapy for metastatic epidural spinal cord compression. Nat Rev Clin Oncol. 2010;7:590\u20138.","journal-title":"Nat Rev Clin Oncol"},{"key":"6385_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"6385_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245\u201351.","journal-title":"J Clin Epidemiol"},{"key":"6385_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/cncr.20756","volume":"103","author":"YM van der Linden","year":"2005","unstructured":"van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW. Dutch bone metastasis study group: prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer. 2005;103:320\u20138.","journal-title":"Cancer"},{"key":"6385_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.radonc.2008.05.018","volume":"89","author":"P Foro Arnalot","year":"2008","unstructured":"Foro Arnalot P, Fontanals AV, Galcer\u00e1n JC, Lynd F, Latiesas XS, de Dios NR, Castillejo AR, Bassols ML, Gal\u00e1n JL, Conejo IM, L\u00f3pez MA. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol. 2008;89:150\u20135.","journal-title":"Radiother Oncol"},{"key":"6385_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.clon.2011.05.004","volume":"23","author":"K Dennis","year":"2011","unstructured":"Dennis K, Wong K, Zhang L, Culleton S, Nguyen J, Holden L, Jon F, Tsao M, Danjoux C, Barnes E, Sahgal A, Zeng L, Koo K, Chow E. Palliative radiotherapy for bone metastases in the last 3 months of life: worthwhile or futile? Clin Oncol (R Coll Radiol). 2011;23:709\u201315.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"6385_CR21","first-page":"47","volume":"2","author":"K Dennis","year":"2011","unstructured":"Dennis K, Zhang L, Holden L, Jon F, Barnes E, Tsao M, Danjoux C, Sahgal A, Zeng L, Koo K, Khan L, Caissie A, Chow E. Functional interference due to pain following palliative radiotherapy for bone metastases among patients in their last three months of life. World J Oncol. 2011;2:47\u201352.","journal-title":"World J Oncol"},{"key":"6385_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0360-3016(98)00174-6","volume":"42","author":"B Jeremic","year":"1998","unstructured":"Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N, Aleksandrovic J, Igrutinovic I. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int J Radiat Oncol Biol Phys. 1998;42:161\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6385_CR23","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0885-3924(01)00359-1","volume":"22","author":"B Jeremic","year":"2001","unstructured":"Jeremic B. Single fraction external beam radiation therapy in the treatment of localized metastatic bone pain. A review. J Pain Symptom Manag. 2001;22:1048\u201358.","journal-title":"J Pain Symptom Manag"},{"key":"6385_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.radonc.2012.12.009","volume":"106","author":"K Dennis","year":"2013","unstructured":"Dennis K, Makhani L, Zeng L, Lam H, Chow E. Single fraction conventional external beam radiation therapy for bone metastases: a systematic review of randomised controlled trials. Radiother Oncol. 2013;106:5\u201314.","journal-title":"Radiother Oncol"},{"key":"6385_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/0360-3016(94)90396-4","volume":"29","author":"NP Mithal","year":"1994","unstructured":"Mithal NP, Needham PR, Hoskin PJ. Retreatment with radiotherapy for painful bone metastases. Int J Radiat Oncol Biol Phys. 1994;29:1011\u20134.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6385_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijrobp.2011.10.080","volume":"84","author":"M Huisman","year":"2012","unstructured":"Huisman M, van den Bosch MA, Wijlemans JW, van Vulpen M, van der Linden YM, Verkooijen HM. Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2012;84:8\u201314.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6385_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3171\/2017.1.SPINE16684","volume":"27","author":"ZA Husain","year":"2017","unstructured":"Husain ZA, Sahgal A, De Salles A, Funaro M, Glover J, Hayashi M, Hiraoka M, Levivier M, Ma L, Mart\u00ednez-Alvarez R, Paddick JI, R\u00e9gis J, Slotman BJ, Ryu S. Stereotactic body radiotherapy for de novo spinal metastases: systematic review. J Neurosurg Spine. 2017;27:295\u2013302.","journal-title":"J Neurosurg Spine"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6385-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6385-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6385-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:12:31Z","timestamp":1606435951000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6385-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6385"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6385-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"24 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of the University of L\u00fcbeck (reference number: 18-254A). The study was conducted in accordance with the principles laid out in the Declaration of Helsinki and in accordance with the principles of Good Clinical Practice.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.R. and S.J. are associate editors of BMC Cancer. Otherwise, the authors declare that they have no competing interest related to the study presented here.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1156"}}